{
    "id": 25834,
    "fullName": "ITGA5 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ITGA5 positive indicates the presence of the ITGA5 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3678,
        "geneSymbol": "ITGA5",
        "terms": [
            "ITGA5",
            "CD49e",
            "FNRA",
            "VLA-5",
            "VLA5A"
        ]
    },
    "variant": "positive",
    "createDate": "12/19/2016",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) combined with Buparlisib (BKM120) resulted in a synergistic effect, demonstrating increased apoptotic activity in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 5105,
                "therapyName": "Buparlisib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PTEN deficient prostate cancer cells expressing ITGA5 did not benefit from Ipatasertib (GDC-0068) treatment in culture, demonstrating no apoptotic activity (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9628,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of A-1331852 and Ipatasertib (GDC-0068) resulted in a synergistic effect, demonstrating increased apoptotic activity in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 5109,
                "therapyName": "A-1331852 + Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9620,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) combined with Ipatasertib (GDC-0068) resulted in a synergistic effect, demonstrating increased apoptotic activity in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 5106,
                "therapyName": "Ipatasertib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9630,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of A-1210477 and A-1331852 did not result in efficacy in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 5110,
                "therapyName": "A-1210477 + A-1331852",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9618,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) resulted in some apoptotic activity, but only at high doses in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 825,
                "therapyName": "Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9629,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-1331852 resulted in minimal apoptotic activity in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 2578,
                "therapyName": "A-1331852",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9627,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of A-1331852 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating increased apoptotic activity in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 5111,
                "therapyName": "A-1331852 + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9619,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PTEN deficient prostate cancer cells expressing ITGA5 did not benefit from Buparlisib (BKM120) treatment in culture, demonstrating little to no apoptotic activity (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9626,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9622,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263) and Buparlisib (BKM120) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 5105,
                "therapyName": "Buparlisib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9623,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Venclexta (venetoclax) and Buparlisib (BKM120) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 5107,
                "therapyName": "Buparlisib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Venclexta (venetoclax) and Pictilisib (GDC-0941) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 5108,
                "therapyName": "Pictilisib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9625,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26936,
            "profileName": "ITGA5 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26937,
            "profileName": "ITGA5 pos PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26938,
            "profileName": "ITGA5 pos PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}